These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26455583)

  • 1. Dissolution of Urinary Bladder Clots in a Dog with Alteplase.
    Pineda C; Guisado A; Aguilera-Tejero E; Lopez I
    J Vet Intern Med; 2015; 29(6):1627-8. PubMed ID: 26455583
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of intravesicular alteplase for thrombolysis in a dog with urinary bladder thrombi.
    Hooi KS; Lemetayer JD
    J Vet Emerg Crit Care (San Antonio); 2017 Sep; 27(5):590-595. PubMed ID: 28749042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of alteplase for the resolution of an intravesical clot in a neonate receiving extracorporeal membrane oxygenation.
    Olarte JL; Glover ML; Totapally BR
    ASAIO J; 2001; 47(5):565-8. PubMed ID: 11575839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Management of Urinary Bladder Clot with Intravesical Tissue Plasminogen Activator Infusion in a Cat.
    Young CS; Racette M; Todd JM
    J Am Anim Hosp Assoc; 2021 May; 57(3):. PubMed ID: 33770160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant tissue-plasminogen activator for aortic thrombolysis in a hypoproteinemic dog.
    Clare AC; Kraje BJ
    J Am Vet Med Assoc; 1998 Feb; 212(4):539-43. PubMed ID: 9491162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of thrombolytic agents.
    Whelan MF; O'Toole TE
    Compend Contin Educ Vet; 2007 Aug; 29(8):476-82; quiz 482, 486. PubMed ID: 17849701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrohematuria and life-threatening anemia attributable to subepithelial vascular ectasia of the urinary bladder in a dog.
    Littman MP; Niebauer GW; Hendrick MJ
    J Am Vet Med Assoc; 1990 May; 196(9):1487-9. PubMed ID: 2187841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava.
    Bliss SP; Bliss SK; Harvey HJ
    J Am Anim Hosp Assoc; 2002; 38(5):431-5. PubMed ID: 12220027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase (Cathflo Activase).
    Middleton G; Ruzevick B
    Clin J Oncol Nurs; 2004 Aug; 8(4):417-8, 420. PubMed ID: 15354930
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA; Hamor RE; Ramsey DT; Vasaune S; Schaeffer DJ
    Am J Vet Res; 1994 Oct; 55(10):1368-70. PubMed ID: 7998691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.
    Langston C; Eatroff A; Poeppel K
    J Vet Intern Med; 2014; 28(2):270-6. PubMed ID: 24438008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly decreased in dogs suffering from diseases predisposing to thrombosis.
    Spodsberg EH; Wiinberg B; Jessen LR; Marschner CB; Kristensen AT
    Vet Clin Pathol; 2013 Sep; 42(3):281-90. PubMed ID: 23944273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary bladder mural hemorrhage associated with systemic bleeding disorders in three dogs.
    O'Brien RT; Wood EF
    Vet Radiol Ultrasound; 1998; 39(4):354-6. PubMed ID: 9710141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution of blood clots in the biliary ducts with a thrombolytic agent infused through nasobiliary catheter.
    Moparty RK; Brown RD; Layden TJ; Chirravuri V; Wiley T; Venu RP
    Gastrointest Endosc; 2002 Sep; 56(3):436-8. PubMed ID: 12196791
    [No Abstract]   [Full Text] [Related]  

  • 16. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis.
    Nguyen TV; Dikun M
    Am J Health Syst Pharm; 2004 Sep; 61(18):1922-4. PubMed ID: 15487882
    [No Abstract]   [Full Text] [Related]  

  • 17. Pilot study of Alteplase (tissue plasminogen activator) for treatment of urinary clot retention in an in vitro model.
    Ritch CR; Ordonez MA; Okhunov Z; Araujo J; Walsh R; Baudin V; Lee D; Badani KK; Gupta M; Landman J
    J Endourol; 2009 Aug; 23(8):1353-7. PubMed ID: 19594375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase use for clotted catheters.
    Macon EJ
    Semin Dial; 2002; 15(1):72. PubMed ID: 11874599
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical use of tissue plasminogen activator for systemic thrombolysis in dogs and cats.
    Diaz DM; Scansen BA; Lake Z; Shropshire S; Orton EC; Guillaumin J
    J Vet Cardiol; 2022 Jun; 41():154-164. PubMed ID: 35364502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Repeated thrombolysis with tenecteplase as a bridge to valvular replacement in a case of preoclusive mitral prosthetic thrombosis].
    Ferreiro-Gutiérrez JL; Ariza-Solé A; Mañas-Jiménez P; Ruiz-Majoral A
    Med Clin (Barc); 2009 Sep; 133(10):402-3. PubMed ID: 19747593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.